Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial

• Published in: Journal of clinical oncology Vol. 41; no. 16_suppl; p. 1007
• Main Authors: Khan, Qamar J., Bohnenkamp, Colleen, Monson, Taylor, Smith, Holly E, Phadnis, Milind A., Raja, Vinay, Elia, Manana, O'Dea, Anne, Crane, Gregory James, Fesen, Mark Robert, Nye, Lauren Elizabeth, Sheehan, Maureen, Pluenneke, Robert E., Al-Rajabi, Raed Moh'd Taiseer, Baranda, Joaquina Celebre, Kasi, Anup, McKittrick, Richard J., Mitchell, Laura, LaFaver, Stephanie, Sharma, Priyanka
• Format: Journal Article
• Language: English
• Published: 01.06.2023

1007 Background: In metastatic breast cancer (MBC), oral capecitabine prescribed at the FDA approved dose of 1250 mg/m 2 twice daily, 14 days on followed by 7 days off, is associated with poor tolerance and high discontinuation rates. Mathematical models suggest a fixed dose, dose dense (7 days on,...